
Opinion|Videos|March 19, 2025
Current and Emerging Uses of ctDNA in the Adjuvant MIUC Setting
Author(s)Matthew Galsky, MD
An expert discusses how medical professionals are increasingly utilizing circulating tumor DNA (ctDNA) and tissue PD-L1 to guide recommendations for adjuvant immune checkpoint inhibitor (ICI) therapy. ctDNA helps monitor minimal residual disease and early treatment response while tissue PD-L1 status aids in predicting ICI efficacy, optimizing patient treatment plans.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Are you using ctDNA and/or tissue PD-L1 to guide recommendations for adjuvant ICI and/or to monitor response to adjuvant ICI?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5































